Cyclerion Therapeutics, Inc. CYCN PHARMA
Company Overview
As of September 8, 2026, Cyclerion Therapeutics, Inc. was acquired by Korsana Biosciences, Inc. in a reverse merger transaction. Cyclerion Therapeutics, Inc., a biopharmaceutical company, engages in the development of treatments for serious diseases serious diseases with novel sGC stimulators in both the central nervous system (CNS) and the periphery. The company is developing Olinciguat, an orally administered vascular soluble guanylate cyclase (sGC) stimulator, which is in Phase 2 clinical trial to treat cardiovascular diseases; and Praliciguat, a systemic sGC stimulator for the treatment of rare kidney disease. It has a license agreement with Akebia to develop, manufacture, medical affair, and commercializes Praliciguat and other related products. The company was incorporated in 2018 and is headquartered in Cambridge, Massachusetts.
Recent Developments
- Dec 2025 Revenue of $2.07M (+3.7% YoY); net profit $-3.53M.
- Trailing 12 Months Year-on-year growth — revenue +3.7%.
- 5-Year Trend Long-term compounding — revenue CAGR -14.4%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | -14.38% |
| 1 Year: | 3.70% |
Stock Price Performance
| 1 Year: | +36.03% |
| 6 Months: | +125.50% |
| 3 Months: | +11.63% |
| 1 Month: | -5.88% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMABelow
- Price vs 200-DMAAbove
- RSI (14)41.24 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- In a confirmed uptrend (50-DMA above 200-DMA).
CONS
- Revenue declined at -14.4% CAGR over 5 years.
- Trading 47.3% below its 52-week high.
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | CYCN Cyclerion Therapeutics, Inc. PHARMA | 3.36 | -0.29 | $2.25M | 0.00% | -54.74% | -98.22% | -14.38% | - |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,123.91 | 37.80 | $1.00T | 0.60% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 269.12 | 31.22 | $648.55B | 1.98% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 248.78 | 70.48 | $439.62B | 2.78% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | MRK Merck & Co., Inc. SPXR3KPHARMA | 148.46 | 118.77 | $366.28B | 2.31% | - | 6.96% | 5.64% | 10.01% |
| 6 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 400.84 | 25.74 | $359.79B | 2.47% | 9.74% | 14.15% | 10.40% | 5.43% |
| 7 | NVS Novartis AG PHARMA | 137.70 | 20.80 | $261.73B | 3.36% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 160.04 | 23.99 | $248.20B | 2.00% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | TMO Thermo Fisher Scientific Inc. SPXR3KPHARMA | 603.02 | 32.49 | $222.97B | 0.29% | 8.14% | 13.51% | 8.81% | 12.95% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Mar 2018 | Jun 2018 | Sep 2018 | Mar 2019 | Jun 2019 | Sep 2019 | Mar 2020 | Jun 2020 | Sep 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | 1.63M | 1.40M | 1.01M | 749.00K | 400.00K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Operating Income | -25.28M | -29.78M | -29.29M | -37.38M | -33.05M | -28.02M | -20.59M | -19.67M | -21.78M | -13.39M | -16.18M | -11.29M | -12.98M | -13.43M | -4.52M | -3.27M | -1.86M | -6.01M | -1.62M | -1.38M | -1.13M | -1.46M | -1.67M | -1.01M | -3.21M | -1.77M |
| Net Income | -25.28M | -29.78M | -29.29M | -37.38M | -32.25M | -27.32M | -20.23M | -19.53M | -18.81M | -6.95M | -16.18M | -11.29M | -12.98M | -13.39M | -10.50M | -6.95M | -4.18M | 7.57M | -1.54M | -1.32M | -723.00K | -1.43M | -324.00K | -976.00K | -3.18M | -1.75M |
| Diluted EPS | - | - | - | - | - | - | - | - | - | - | -0.45 | -0.26 | -0.30 | -6.16 | -4.83 | -3.20 | -1.83 | 2.72 | -0.62 | -0.53 | -0.29 | -0.56 | -0.11 | -0.30 | -0.76 | -0.41 |
| R&D Expense | 21.51M | 22.25M | 21.50M | 26.40M | 25.76M | 22.30M | 16.82M | 13.79M | 13.70M | 8.09M | 12.05M | 7.03M | 9.74M | 10.22M | 1.41M | 572.00K | 339.00K | 580.00K | 44.00K | 105.00K | 81.00K | 36.00K | 56.00K | 348.00K | 730.00K | - |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | - | 4.51M | 2.30M | - | 297.00K | 0 | 2.00M | 2.07M |
| Cost of Revenue | - | - | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - | - | - |
| Operating Expenses | - | - | - | - | 18.84M | 9.65M | 5.63M | 7.05M |
| Operating Income | -115.25M | -125.04M | -81.27M | - | -18.54M | -9.65M | -3.63M | -4.97M |
| EBITDA | - | - | - | - | -18.48M | -9.65M | -3.63M | -4.97M |
| Interest Expense | - | - | - | 16.00K | - | - | - | - |
| Pretax Income | - | - | - | - | -18.25M | -12.59M | -3.06M | -3.53M |
| Tax Provision | - | - | - | - | - | - | - | - |
| Net Income | -115.25M | -123.01M | -77.80M | - | -44.08M | -5.26M | -3.06M | -3.53M |
| Diluted EPS | - | - | - | - | -20.28 | -2.25 | -1.21 | -1.11 |
| R&D Expense | 87.72M | 95.14M | 56.41M | 37.64M | 5.98M | 1.51M | 286.00K | 959.00K |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|
| Total Assets | - | 7.40M | 186.48M | 115.38M | 59.33M | 18.08M | 13.37M | 9.57M | 9.98M |
| Total Equity | -8.57M | -10.45M | 97.73M | 59.49M | 48.25M | 10.45M | 11.29M | 8.85M | 9.09M |
| Cash & Equivalents | - | - | 94.89M | 54.40M | 53.96M | 13.38M | 7.57M | 3.23M | 3.24M |
| Current Liabilities | - | 17.85M | 18.25M | 16.95M | 11.09M | 7.63M | 2.09M | 725.00K | 900.00K |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -97.50M | -102.22M | -72.49M | -36.52M | -40.61M | -21.25M | -4.33M | -3.31M |
| Investing Cash Flow | -3.44M | -6.71M | 18.00K | 1.46M | 0 | 10.40M | 0 | - |
| Financing Cash Flow | 100.94M | 211.57M | 28.09M | 30.79M | 29.00K | 5.02M | 0 | 3.32M |
| Capital Expenditure | -3.44M | -6.89M | -1.52M | -7.00K | -0 | - | - | - |
| Free Cash Flow | -100.94M | -109.10M | -74.01M | -36.52M | -40.61M | - | - | - |
Ratios (Annual)
Figures in %.
| Metric | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - | - | - | - |
| Operating Margin % | - | -2,774.3% | -3,539.4% | - | -6,242.4% | - | -181.4% | -239.8% |
| Net Margin % | - | -2,729.3% | -3,388.6% | - | -14,841.1% | - | -152.8% | -170.1% |
| ROE % | 1,103.4% | -125.9% | -130.8% | - | -421.7% | -46.6% | -34.5% | -38.8% |
| ROCE % | 1,103.4% | -74.3% | -82.6% | - | -177.4% | -85.5% | -41.0% | -54.7% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Kalehua Capital Management LLC | 35.28% | 1.65M | $38.84M |
| 2 | FMR, LLC | 13.88% | 649.55K | $15.28M |
| 3 | Balyasny Asset Management LP | 6.78% | 317.51K | $7.47M |
| 4 | Adar1 Capital Management, LLC | 6.38% | 298.76K | $7.03M |
| 5 | Braidwell LP | 3.35% | 156.89K | $3.69M |
| 6 | Citadel Advisors Llc | 1.28% | 59.80K | $1.41M |
| 7 | Geode Capital Management, LLC | 0.98% | 45.85K | $1.08M |
| 8 | Vanguard Capital Management LLC | 0.66% | 30.91K | $727.12K |
| 9 | Rangeley Capital, LLC | 0.52% | 24.31K | $571.77K |
| 10 | HRT Financial LP | 0.47% | 22.05K | $518.71K |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for CYCN
Cyclerion Therapeuticsinc Stock Price Forecast. Should You Buy CYCN? - StockInvest.us
<a href="https://news.google.com/rss/articles/CBMiSEFVX3lxTE92Sm8zZDJ1RWk2Y2Nnb25jV2RITm9Va1N2cE5rX3p2UktjaXpGc01NVkZEajkzZnJvUFZxSmUzdHlkR04xYjZPcw?oc=5" target="_blank">Cyclerion Therapeuticsinc Stock Price Forecast. Should You Buy CYCN?<…
Penny Stock CYCN Surged More Than 300% Yesterday. Why, And Should You Chase the Rally Here? - Barchart.com
<a href="https://news.google.com/rss/articles/CBMiywFBVV95cUxNUHVCTVBCM0xfWG1nZHpnZ05pNk1kS3cyUUFZZ0RWXzVtcXVpT3dJUFFMcXBIVVN2LVlGVnI3YTdJdi1qbjZJcUJDbXA2YUFpZGZITHZwYUV1cGozb0dqRzNidkwyX3I5dzBkYmVHODNyRUpGQWQ5UVNUaTV4Sk5pUVQ0YmdrWkpQZDlxeF…
Cyclerion Therapeutics (CYCN) sets CVR date for Korsana merger - Stock Titan
<a href="https://news.google.com/rss/articles/CBMitgFBVV95cUxOX1ktUU8tRm0zNHJFcWhzZGNuXy1ZV1pwcGJBbHRsUFpKcDFMbGthZnAwaXJKQ0dIQVBlTW1kNl9pcXh5R0J6cy1IVF9pTVEzejdTcW80bDY1ZHE4VWw0MmFZdnhyaFpsWVhtX2ZrYzRWUlJNTkprZ2lRUHNvOERZRkdJMXY0RXc4S2c5QU…
Why is Biotech Stock Cyclerion Therapeutics, Inc. (Nasdaq: CYCN) Gaining? - Investorideas.com
<a href="https://news.google.com/rss/articles/CBMikAFBVV95cUxNdHpldnBQOGlIV3k2QVkzNThWR0gyWl9nMTE5X2dqQVRoUmNtRHlqMWlXSVhmakc0ZXlGd2tNcGVVMUpuN3BzOTRmajhtNkFiblZHN1JWMUdXUkZhS3VBaFZzcWZlNi1RaE5PVE1lVUFXTFZ1Mm5yc1FxYmtFS3BsbzFwSDBWb3Y0WlJ2WF…
CYCN Stock Is Soaring 274% Today — What Is Fueling The Rally? - Stocktwits
<a href="https://news.google.com/rss/articles/CBMiywFBVV95cUxQcUV6TV9VVFdXendxcmlzc2dTR3JIRnFxSkl4UUJUaUpWSktJWVBaTjY4ajgtRFZ4T3NzWTJNdUx1U2tXeFduYjJ0RWgxXzhwMzFVWkJ3V1JBdVItREpCNjVTMHM5WXREZHhOQkM2UlF1SlY1TkNxVThHWW1TdERHcVRTQ1dhQWtGR0wtNn…
CYCN - Finviz
<a href="https://news.google.com/rss/articles/CBMiRkFVX3lxTE9DbllSYmtIblljbExpZGloalBhSVN2THZXVkxVQnZ2Q01JUVFxUTk2YjRSN3VhTFJzSkhIRnFiQk11M0lJcXc?oc=5" target="_blank">CYCN</a> <font color="#6f6f6f">Finviz</font>…
CYCN — Frequently Asked Questions
What is the current share price of Cyclerion Therapeutics, Inc. (CYCN)?
As of 2026-09-19 21:16 PDT, Cyclerion Therapeutics, Inc. (CYCN) trades at $3.36 on NasdaqCM. Its 52-week range is $1.08 to $6.38.
What is the market capitalisation of CYCN?
Cyclerion Therapeutics, Inc. (CYCN) has a market capitalisation of $2.25M on NasdaqCM.
What is the P/E ratio of CYCN?
CYCN trades at a trailing price-to-earnings (P/E) ratio of -0.29. The industry average P/E is 24.83. Its price-to-book (P/B) ratio is 19.68.
What is the return on equity (ROE) of CYCN?
CYCN has a return on equity (ROE) of -98.22%. Its return on capital employed (ROCE) is -54.74%.
Is CYCN a good stock to buy?
This page provides a data-driven analysis of Cyclerion Therapeutics, Inc. (CYCN), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.